Innovative Alzheimer's Pilot Study Launched by Arizona Organizations in Collaboration with AmBARI Healthcare

Innovative Alzheimer's Pilot Study Launched by Arizona Organizations in Collaboration with AmBARI Healthcare



In an exciting development in the fight against Alzheimer's disease, a coalition of esteemed organizations including AmBARI Healthcare, the Phoenix VA Health Care System, the Arizona Veterans Research and Education Foundation, and the Young Blood Institute, have signed a Cooperative Research and Development Agreement (CRADA). This collaboration aims to examine a pilot clinical study that tests an advanced Therapeutic Plasma Exchange (TPE) treatment among veterans diagnosed with mild cognitive impairment (MCI) and early-stage Alzheimer's disease.

The pilot study, identified as the AmβARI study (VA Protocol #1859907), will enroll a maximum of 56 veteran participants. It is designed as a randomized, controlled trial to assess the effectiveness of a comprehensive TPE protocol. The primary goal of this innovative research is to track changes in the brain associated with amyloid build-up, employing advanced imaging techniques, specifically using PET-CT scans with the NAV-4694 tracer.

Led by Dr. S. Mitchell Harman, MD, PhD, from the Phoenix VA Health Care System, the study’s protocol was developed in conjunction with researchers from both the Young Blood Institute and AmBARI Healthcare. The critical funding for this endeavor comes from AmBARI, thanks to its strategic partnerships that bolster access to cutting-edge apheresis systems, biomarkers, and imaging technology.

The background knowledge fueling this study draws from previous successful trials, including the Grifols AMBAR trial, which reported a noteworthy 61% success rate in halting or delaying disease progression among early to moderate Alzheimer’s patients. This research, which involved 498 participants, and the Ace Alzheimer Center in Barcelona, which has executed over 2,100 full-volume procedures as standard clinical practice, have laid significant groundwork for the current pilot study.

Elijah J. Ditter, the Medical Center Director at the Phoenix VA Health Care System, expressed optimism about this CRADA, highlighting its role in facilitating innovative research that directly impacts veterans living with Alzheimer’s. “Our commitment to exploring new, promising treatments remains steadfast,” he asserted, emphasizing the importance of delivering tangible improvements in care.

In response, Dr. Samuel M. Aguayo, MD, also from the Phoenix VA Health Care System, emphasized the institution's strong legacy in translating research into practical applications. He underscored that this study will rigorously evaluate the TPE approach within a veteran demographic, promoting advancements in translational medicine.

Jeremy Greene, Executive Director of the Arizona Veterans Research and Education Foundation, added that partnerships with reputable biomedical research institutes like the Young Blood Institute are crucial. They allow the VA to explore novel treatment modalities that can potentially benefit both veterans and the wider population.

Professor Colin Masters, MD, Global Coordinating Principal Investigator for the Young Blood Institute, responded to the study’s objectives with enthusiasm. He acknowledged that the new TPE protocol builds on successful foundational research found in both the AMBAR trial and clinical realities from Barcelona, incorporating the latest developments in blood and PET imaging technologies.

Mark Urdahl, CEO of both AmBARI Healthcare and the Young Blood Institute, expressed gratitude for the collaboration opportunities presented by the Arizona Veterans Research and Education Foundation and the Phoenix VA. His extensive career in translating advanced technologies into clinical practice aligns with the overarching goal of using this study to provide effective care solutions for veterans.

Under the governance of the Phoenix VA Institutional Review Board (IRB) and in full compliance with federal laws, the study represents a pivotal step in researching Alzheimer’s treatment. The Arizona Veterans Research and Education Foundation, established as a 501(c)(3) entity, aims to support research initiatives that ultimately serve veterans and improve their health care systems through innovative approaches.

The Phoenix VA Health Care System provides essential healthcare services to over 130,000 veterans in Arizona and is dedicated to advancing research that centers on the needs of veterans. With substantial backing from its community partners, the foundation is poised to introduce potentially life-changing therapies based on the outcomes of this novel study.

For more information on these organizations or to follow the ongoing study, please visit their respective websites. This pioneering initiative stands at the forefront of combining rigorous scientific research with the pressing needs of veterans battling cognitive decline, ensuring their treatment options are enhanced for a better quality of life.

Topics Health)

【About Using Articles】

You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.

【About Links】

Links are free to use.